• Katarzyna Hryniewicz, Yader Sandoval, Michael Samara, Mosi Bennett, Barry Cabuay, Ivan J Chavez, Susan Seatter, Peter Eckman, Peter Zimbwa, Aaron Dunn, and Benjamin Sun.
• From the *Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota; †Division of Cardiology, Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota; ‡Department of Intensive Care Medicine at Abbott Northwestern Hospital, Minneapolis, Minnesota; and §Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
• ASAIO J. 2016 Jul 1; 62 (4): 397-402.

AbstractMortality due to refractory cardiogenic shock (RCS) exceeds 50%. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) has become an accepted therapy for RCS. The aim of our study was to evaluate outcomes of patients with RCS treated with percutaneous VA-ECMO (pVA-ECMO). Retrospective review of patients supported with VA-ECMO at our institution in 2012-2013. Clinical characteristics, bleeding, vascular complications, and outcomes including survival were assessed. A total of 37 patients were supported with VA-ECMO for RCS. The majority of VA-ECMO (76%) was placed in the catheterization laboratory. Nearly half (49%) of the patients presented with acute myocardial infarction. Seven patients (19%) underwent insertion of pVA-ECMO in the setting of cardiopulmonary resuscitation with mechanical chest compression device. Median duration of support was 5 days. Index hospitalization, 30-day, and 1-year survival were 65%, 65%, and 57%, respectively. Survival rate for discharged patients was 87.5% with a median follow-up of 450 days. Refractory cardiogenic shock supported with pVA-ECMO is associated with an improved survival in patients with a traditionally poor prognosis.

14 keywords...

hide…